Psychedelic Stocks Psychedelic Companies Accelerating Their Mental illness Programs Following Approval Of Johnson & Johnson’s (NYSE:JNJ) Depression Treatment By Larry Zweig January 05, 2021 The psychedelic medicines industry saw tremendous growth in 2020 and the growth could continue in 2021 as more cases of mental illness continue globally. The World Health Organisation has estimated that each year there are more th...
